List of Excipients in Branded Drug STRIANT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Columbia Laboratories Inc	STRIANT	testosterone	55056-3060	ANHYDROUS LACTOSE
Columbia Laboratories Inc	STRIANT	testosterone	55056-3060	CARBOMER 934
Columbia Laboratories Inc	STRIANT	testosterone	55056-3060	HYPROMELLOSE
Columbia Laboratories Inc	STRIANT	testosterone	55056-3060	LACTOSE MONOHYDRATE
Columbia Laboratories Inc	STRIANT	testosterone	55056-3060	MAGNESIUM STEARATE
Columbia Laboratories Inc	STRIANT	testosterone	55056-3060	POLYCARBOPHIL

Striant Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Striant is a discontinued testosterone buccal system that delivered 30 mg of testosterone twice daily through adhesion to the gum above an incisor. Its core formulation used hydroxypropyl cellulose, carbomer 934P, magnesium stearate, and colloidal silicon dioxide. The commercial opportunity is not a simple generic copy. It is a differentiated buccal testosterone product using improved mucoadhesion, lower local irritation, better taste control, and more reliable residence time under a 505(b)(2) or equivalent regulatory strategy.

What is Striant and how did the product work?

Striant was approved by the U.S. Food and Drug Administration for testosterone replacement in adult men with hypogonadism associated with a deficiency or absence of endogenous testosterone.[1] The product was a small mucoadhesive buccal tablet applied to the gum twice daily.

Attribute	Striant profile
Active ingredient	Testosterone
Dose	30 mg per buccal system
Route	Buccal, applied to upper gum
Administration	One system in the morning and one in the evening
Original developer	Columbia Laboratories
FDA pathway	NDA 21-656
Dosage form	Mucoadhesive buccal tablet
Primary formulation function	Attachment to gingival mucosa and controlled testosterone release
Current commercial status	Discontinued from U.S. commercial distribution

The system was designed to remain attached for several hours while releasing testosterone through the buccal mucosa. Unlike oral testosterone capsules, buccal delivery avoids substantial gastrointestinal degradation and first-pass hepatic metabolism. Unlike injectable testosterone, it does not require a clinic visit or needle administration.

What excipients were used in Striant?

The Striant prescribing information identifies four inactive ingredients: hydroxypropyl cellulose, carbomer 934P, magnesium stearate, and colloidal silicon dioxide.[1]

Excipient	Likely formulation role	Strategic relevance
Hydroxypropyl cellulose	Film former, binder, matrix former, and mucoadhesive-support polymer	Controls tablet structure, hydration, and drug release
Carbomer 934P	Mucoadhesive polymer and viscosity-building agent	Provides adhesion to the gingival surface after hydration
Magnesium stearate	Lubricant	Supports tablet manufacture and ejection
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and blend uniformity

The formulation strategy was conventional but commercially useful: a cellulose-based matrix combined with a high-molecular-weight carbomer. Carbomer provides strong adhesion after hydration, while hydroxypropyl cellulose can moderate swelling and contribute to cohesive matrix formation.

Why carbomer and hydroxypropyl cellulose matter

Carbomer concentration has a direct effect on adhesion, swelling, release rate, and local mouthfeel. Excessive carbomer can increase gel strength, prolong residence, and create a foreign-body sensation. It can also increase mucosal irritation if the hydrated polymer remains concentrated at one site.

Hydroxypropyl cellulose can reduce matrix brittleness and improve tablet handling. Its grade, particle size, substitution profile, and molecular weight affect hydration and release. A higher-viscosity grade may extend residence and slow drug liberation, but may also produce an elastic or gummy residue.

The commercial formulation challenge is to maintain attachment without creating a large swollen mass. The optimal product must remain in place during talking, eating, and drinking while minimizing the need for replacement after accidental detachment.

What excipient strategy could improve on Striant?

A successor formulation should focus on four performance targets: adhesion, release control, local tolerability, and manufacturability.

Mucoadhesive polymer optimization

A modern formulation program could evaluate:

• Carbomer 934P and other pharmacopeial carbomer grades
• Polycarbophil
• Hydroxypropyl cellulose with controlled viscosity
• Hydroxypropyl methylcellulose
• Sodium carboxymethylcellulose
• Chitosan or thiolated polymers
• Povidone and copovidone as secondary matrix polymers

The highest-value opportunity is a lower-polymer system that achieves the same residence time with less bulk. Polymer combinations can produce stronger adhesion at lower total excipient loading than carbomer alone.

Thiolated polymers may provide stronger interaction with mucin through disulfide exchange. Their commercial value would depend on regulatory acceptability, impurity control, reproducible substitution, and long-term stability. They could support composition, manufacturing, and performance patent claims, but they would also increase development complexity.

pH and local irritation control

Carbomer systems can create an acidic microenvironment depending on grade, neutralization state, and formulation composition. A reformulated product could use buffering agents or a partially neutralized polymer system to reduce mucosal discomfort.

Potential excipient approaches include:

• Low-level phosphate or citrate buffering
• Controlled neutralization of carbomer
• Polyol-based plasticization
• Reduced ionic strength to preserve polymer adhesion
• Taste-masking agents that do not increase saliva-mediated disintegration

Buffer selection must account for testosterone stability, polymer swelling, saliva compatibility, and local tolerability. A high-buffer-load tablet could weaken carbomer adhesion or increase erosion.

Taste and mouthfeel engineering

Testosterone is lipophilic and can produce an unpleasant taste or lingering oral sensation. Taste masking can be approached through:

• Hydrophobic polymer barriers
• Ion-pair or complexation strategies
• Microencapsulation
• Lipid-based drug dispersion
• Sweetener and flavor systems compatible with buccal residence
• Surface coating on the non-mucosal side of a bilayer system

A bilayer buccal tablet is commercially attractive because it can place the mucoadhesive layer against the gum and use an impermeable or low-permeability backing layer toward the oral cavity. This configuration can improve unidirectional drug flux, reduce swallowed drug, and limit taste exposure.

Moisture and stability control

The main stability risks are polymer hydration during manufacturing or storage, changes in tablet hardness, testosterone degradation, and loss of adhesion after moisture exposure.

A successor product would likely need:

• Low-moisture excipient grades
• High-barrier unit-dose packaging
• Desiccant-supported bottle packaging or foil blisters
• Tight control of residual water
• Moisture sorption testing by excipient lot
• Stability testing after opening and repeated package exposure

Colloidal silicon dioxide can improve powder flow and reduce some processing problems, but it does not replace moisture-barrier packaging. Magnesium stearate level and blending time also require control because excessive lubrication can reduce tablet hardness and slow wetting.

What patents protect Striant and its formulation?

The relevant intellectual-property categories are more important than the historical product name. A new sponsor would need to evaluate:

1. Testosterone buccal delivery compositions.
2. Mucoadhesive polymer combinations.
3. Bilayer or backing-layer buccal systems.
4. Dose-release profiles and residence-time specifications.
5. Methods of treating testosterone deficiency.
6. Manufacturing processes for direct compression or controlled hydration.
7. Packaging systems that preserve low moisture.

Striant’s original composition patents and method-of-use patents are now likely to have limited blocking value because the product was approved more than two decades ago. The commercial freedom-to-operate analysis should focus on later patents covering specific polymers, bilayer architecture, testosterone particle engineering, permeation enhancers, and buccal delivery platforms.

A new product could seek patent protection around:

• A defined carbomer-to-cellulose ratio
• A specific polymer molecular-weight range
• A tablet that remains attached for a specified period
• A reduced-irritation pH range
• A unidirectional release system
• A testosterone particle-size distribution
• A protective backing layer
• A packaging system that limits moisture uptake

Broad claims covering “testosterone in a mucoadhesive buccal tablet” would face substantial prior-art risk. Narrow, experimentally supported claims tied to residence time, release kinetics, mucosal tolerability, or a specific excipient architecture would be more defensible.

What is the FDA regulatory status of Striant?

Striant was approved under an NDA rather than an ANDA. Its U.S. commercial discontinuation means the product is not a current commercial competitor in the testosterone market.[2]

The regulatory route for a successor depends on how closely it matches the historical product.

Development path	Appropriate use	Commercial implication
ANDA under section 505(j)	Same active ingredient, dosage form, strength, route, and pharmaceutical equivalence to an eligible reference product	Lower development cost but limited differentiation
505(b)(2) NDA	Modified excipients, release profile, backing layer, dosing schedule, or clinical use relying partly on prior findings	Supports differentiated claims and potentially stronger pricing
Full NDA	Materially new delivery technology or clinical profile	Highest cost and longest development timeline

A materially different mucoadhesive system would likely be better positioned as a 505(b)(2) product. A sponsor would need to address local safety, systemic exposure, adhesion performance, dose proportionality, residual drug after detachment, and effects of eating and drinking.

Are there Paragraph IV challenges or generic-entry risks?

No active, high-profile Paragraph IV litigation against Striant is a central current market issue. The principal generic risk is historical rather than immediate: a sponsor could pursue a testosterone buccal tablet if the regulatory reference-product pathway and FDA listing status support an ANDA.

A copy product would face several practical barriers:

• Small and uncertain market demand
• Need to reproduce reliable gingival adhesion
• Local irritation and oral safety requirements
• Manufacturing complexity relative to topical gels
• Limited physician familiarity with buccal testosterone
• Commercial competition from established oral, topical, nasal, and injectable products

A 505(b)(2) entrant could reduce direct substitutability and avoid competing solely on price. The strongest launch position would combine testosterone delivery with a measurable adherence advantage.

How does Striant compare with competing testosterone products?

Product category	Main advantage	Main limitation	Excipient opportunity
Buccal testosterone	Avoids injections and may reduce gastrointestinal exposure	Oral adhesion, taste, local irritation	Better polymer system and bilayer design
Topical gel	Familiar, flexible dosing	Transfer risk and daily skin application	Improved permeation and low-transfer vehicles
Oral testosterone undecanoate	Convenient oral administration	Food effects, systemic exposure, monitoring	Lipid and self-emulsifying systems
Nasal testosterone	Low systemic accumulation and local dosing	Multiple daily administrations and nasal tolerability	Mucoadhesive nasal excipients
Injectable testosterone	Long dosing interval and established efficacy	Needles, peaks and troughs, administration burden	Depot excipients and injection tolerability
Pellets	Long duration	Minor surgical procedure	Biodegradable matrices and release control

Striant’s most credible competitive advantage is local, needle-free delivery with potentially lower transfer risk than topical gels. Its main weakness is the need for repeated placement on the gum.

What commercial opportunities exist for a Striant-like product?

A differentiated buccal testosterone product

The most attractive opportunity is a once-daily or lower-frequency buccal product with improved adhesion and reduced oral residue. A formulation that remains attached through normal meals could support a meaningful adherence claim.

A pediatric or adolescent formulation

This area would carry significant clinical and regulatory complexity. A lower-dose mucoadhesive system could be commercially relevant in selected endocrine indications, but it would require a separate development strategy and would not be a simple extension of the adult product.

A combination or adjunctive delivery platform

The Striant platform could be adapted for other lipophilic hormones or locally absorbed drugs. The strongest platform value would come from a polymer and backing-layer technology that can support several active ingredients without relying on testosterone-specific claims.

Licensing and platform transactions

A drug-delivery company with validated mucoadhesive technology could license:

• Polymer composition patents
• Bilayer tablet manufacturing
• Buccal permeation technology
• Low-moisture packaging
• Oral residence-time testing methods

The most credible transaction asset would be a formulation with human pharmacokinetic data and demonstrated local tolerability. Excipient selection alone has limited licensing value unless it produces a measurable clinical or manufacturing advantage.

How strong is the commercial patent estate for a new Striant-like product?

A new estate would be moderate if limited to known excipients and weakly differentiated composition claims. It would be stronger if the sponsor generated comparative data showing:

• Longer residence than a conventional carbomer system
• Lower mucosal irritation
• Lower swallowed fraction
• More consistent testosterone exposure
• Better performance after food and beverage exposure
• Fewer daily applications
• Improved stability at elevated humidity

Patent strength would depend on claim scope, experimental support, freedom to operate, and the ability to prevent substitution with a different polymer system. Formulation patents should be paired with method-of-use, manufacturing, and device or packaging claims.

What generic launch scenarios exist for Striant?

Three launch scenarios are commercially realistic.

Low-cost copy

A sponsor reproduces the original 30 mg buccal tablet using substantially equivalent excipients. This strategy minimizes clinical differentiation but faces a small addressable market and limited physician demand.

Improved 30 mg buccal tablet

A sponsor retains the dose and route but improves adhesion, taste, and packaging. This product could pursue a 505(b)(2) strategy and compete on patient convenience.

Next-generation lower-frequency system

A sponsor develops a stronger mucoadhesive and controlled-release system that reduces application frequency. This has the highest commercial upside but requires the most clinical, regulatory, and patent investment.

Key Takeaways

• Striant used testosterone 30 mg in a mucoadhesive buccal tablet administered twice daily.
• The labeled excipients were hydroxypropyl cellulose, carbomer 934P, magnesium stearate, and colloidal silicon dioxide.
• The main formulation opportunity is improved residence time without increased oral bulk or mucosal irritation.
• Bilayer architecture, controlled polymer hydration, taste masking, and moisture-resistant packaging are the most relevant development levers.
• A differentiated successor is more likely to fit a 505(b)(2) strategy than a conventional ANDA strategy.
• The current commercial opportunity is limited for an exact copy but more attractive for a lower-frequency, better-tolerated buccal testosterone system.
• New patent value would come from defined polymer ratios, residence-time performance, release control, manufacturing, and packaging rather than broad claims to testosterone buccal delivery.

FAQs

Can Striant excipients be replaced in a generic formulation?

Yes. A generic formulation must meet pharmaceutical equivalence and bioequivalence requirements, but the excipient composition can differ within applicable FDA limits if the product performs equivalently and remains safe and effective.

Is carbomer 934P essential to testosterone buccal delivery?

No. Carbomer 934P was used in Striant, but polycarbophil, cellulose derivatives, chitosan, and other mucoadhesive polymers may provide suitable performance. Each substitution changes adhesion, swelling, release, and tolerability.

Could a once-daily Striant replacement obtain new patent protection?

Yes. Protection could be pursued for a controlled-release system, polymer architecture, backing layer, residence-time profile, or manufacturing process. The claims would need support from comparative formulation and clinical data.

What is the biggest manufacturing risk for a Striant-like tablet?

The main risk is inconsistent adhesion and release caused by variation in polymer hydration, tablet hardness, lubrication, moisture exposure, and excipient particle properties.

Would a Striant replacement compete mainly with testosterone gels?

Yes. Topical gels are a major comparator because both products are needle-free. A buccal product would need to show a practical advantage, such as lower transfer risk, less daily handling, stronger adherence, or more predictable exposure.

References

1. U.S. Food and Drug Administration. (2003). Striant testosterone buccal system prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Striant, NDA 21-656.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2015). Testosterone products: Drug safety communication and labeling changes.
5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary.